PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference ( Edinburgh, UK ; November 12-15 ) Presentation and poster by Dr.
Matthew Morrow , VP of Translational Sciences Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enrichment in hallmark interferon alpha, interferon gamma and inflammatory molecular signatures in papilloma tissue of responders Poster by Dr. Jeffrey Skolnik , SVP of Clinical Development Abstract Title: Clinical response to INO-3107 treatment for recurrent respiratory papillomatosis is associated with CD4 and CD8 T-Cell activity and cytotoxicity in patient airways Vaccines Summit ( Boston, MA ; November 13-15 ) Keynote presentation by Dr. Dave Liebowitz , SVP Early-Stage Clinical Development Abstract Title: DNA Medicines Vaccine Platform for both Prophylactic and Therapeutic Applications: Case Studies in Ebola and Recurrent Respiratory Papillomatosis Abstracts from these conferences will be made available on INOVIO's website following each presentation.
About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela.